Navamedic ASA: Enters into long-term agreement for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
Navamedic ASA: Enters into long-term agreement for distribution of GoNitro®* in the Nordics

   Oslo, November 20, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a preliminary long-term agreement with G. Pohl-Boskamp GmbH & Co. KG for the Nordic launch and commercialisation of GoNitro®*, a new nitroglycerin sublingual powder formulation for acute relief of an attack or prophylaxis of angina pectoris.

 

"We are very pleased to announce a planned extension of our partnership with Pohl-Boskamp for distribution of the prescription medicine GoNitro (nitroglycerin) sublingual powder in the Nordic markets. GoNitro is used to treat adults for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease, the most common type of heart disease. A Nordic approval of GoNitro would enhance the treatment options available to the more than 1.2 million Nordic patients suffering from stable angina, as the first and only short-acting nitrate in a stabilized crystal granule form available in single dose packets," says Tom Rönnlund, Chief Executive Officer of Navamedic.

 

Pohl-Boskamp has developed a new, patented nitroglycerin oral powder formulation for sublingual administration with the proposed brand name GoNitro®. The product has been submitted for regulatory review in the Nordic markets.

 

"As Pohl-Boskamp recently have submitted the product for regulatory review in the Nordic markets, with expected approval late 2018 or early 2019, we are jointly evaluating the best approach to the market after an approval and we have entered into a preliminary agreement to allow immediate initiation of this work, " says Rönnlund.

 

Pohl-Boskamp is also the market authorisation holder for Nitrolingual® Pumpspray, a medication already approved in Norway, Sweden and Denmark, as an oral spray of nitroglycerine used for relief or prevention of sudden attacks of chest pain associated with angina pectoris caused by heart disease. Nitrolingual® Pumpspray has been marketed by Navamedic in the Nordic region since early 2016. Clinical data indicate that the sublingual absorption of nitroglycerin is higher following the administration of GoNitro® compared to Nitrolingual® Pumpspray.

 

"Short-acting nitrates are the current standard of care for acute relief of an angina attack for patients suffering from coronary artery disease, affecting 3-7% of the adult population. If approved, GoNitro would be the first new dosage form in the short-acting nitrate category in nearly 20 years, offering Nordic healthcare providers and patients a new option for management of angina attacks," says Rönnlund.

 

The GoNitro® agreement is the third recent partnership for original pharmaceutical products scheduled for launches in 2018 and 2019, leveraging on Navamedic's regulatory, sales and marketing capabilities in the hospital and pharmacy sectors. The company is also working on an additional pipeline of exciting pharmaceuticals with launches scheduled for the coming 6-24 months, bringing the company back on a growth track in the medium-term perspective following the discontinuation of the Aspen agreement.

 

"The planned long-term agreement with Pohl-Boskamp is in line with our strategic approach of further strengthening and expanding our pharmaceutical products portfolio and entering solid, long-term partnerships. We currently have some great new pharmaceuticals in the pre-launch and launch phase and are looking forward to bringing these new treatment options to patients and physicians across the Nordics," says Tom Rönnlund,

 

 

For further information, please contact:

 

Tom Rönnlund, CEO, Navamedic ASA

Telephone: +46 727 320 321

 

 

* GoNitro® is the proposed brand name for the nitroglycerin sublingual powder in the regulatory approval application submitted to Nordic authorities.

 

 

ABOUT Angina Angina is the name for pain or discomfort in the chest. It occurs when the heart isn't getting enough oxygen from blood. Angina is not a disease, but a symptom of another heart condition. Heart disease is a very serious health issue. It is the number one cause of death in the world. Men and women experience angina about equally. Many patients who have angina are not taking medicine to alleviate the pain.

 

ABOUT GoNitro®

Fast-acting GoNitro® (nitroglycerin) sublingual powder is approved in the U.S. by FDA (U.S. Food & Drug Administration) for the prevention and treatment of angina. GoNitro® is intended to be used as soon as symptoms of angina occurs, or 5 to 10 minutes before such symptoms are anticipated. GoNitro® is provided in small, single-dose packets that are easy to carry for the patient.

 

ABOUT NAVAMEDIC:

Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to patients, hospitals and pharmacies in the Nordic and Benelux markets. The Group's Medtech business has developed and is currently introducing the next generation of digital urine meter Sippi®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

 

ABOUT G. Pohl-Boskamp GmbH & Co. KG

Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for more than 175 years with commercialized products in more than 45 countries. Through close collaboration with its partners abroad, Pohl-Boskamp focuses on developing and marketing products that positively impact patients' quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology. For more information, visit www.pohl-boskamp.de.

 

 

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Moatable, Inc. Concludes the Tender Offer for Class A Shares

Updated Category News Views 139

Moatable, Inc. Completes Tender Offer for Class A Shares Moatable, Inc. (Pink Limited Market: MTBLY), a premier US-based SaaS company, has announced the successful completion of its fixed price tender offer. The company aimed to repurchase an impressive 225 million Class A ordinary shares. Each share has a par value of $0.001, and they can also be represented by American...

Continue Reading
Armstrong World Industries' Q4 Earnings: What Investors Need

Updated Category News Views 164

Armstrong World Industries Q4 Earnings Report Let’s dive right into this latest earnings report from Armstrong World Indus (NYSE:AWI) that just hit the streets. Released on February 24, 2026, bright and early, it’s got both good news and some not-so-great tidbits that every investor should chew on. Honestly, missing earnings estimates by a margin like -3.59% just...

Continue Reading
Batteries Plus Enhances Partnership for Educational Safety Needs

Updated Category News Views 254

Batteries Plus Enhances Partnership for Educational Safety Needs From Campus Fleets to Classroom Security, Local Teams Support Operational Readiness for Schools and Universities Nationwide Batteries Plus is deepening its partnerships with K-12 districts, colleges, and universities by supplying a broad range of comprehensive battery, lighting, and security system support....

Continue Reading
Exciting Developments in Houston: The RO Project Advances

Updated Category News Views 453

Transwestern Launches Next Phase of The RO Development Transwestern, a prominent commercial real estate firm headquartered in Houston, has taken a monumental step forward by breaking ground on the next phase of The RO. This innovative project aims to redefine the River Oaks neighborhood, representing a significant addition to the area that harmonizes various aspects of...

Continue Reading
BMO Financial Group Plans Large Share Repurchase Initiative

Updated Category News Views 95

BMO Financial Group's Strategic Share Buyback Program Bank of Montreal (TSX:BMO)(NYSE:BMO) has announced an ambitious plan to repurchase up to 20 million common shares through a normal course issuer bid. This initiative is designed to strengthen the bank's capital structure and reflects its confidence in its business fundamentals. Details of the Share Repurchase Plan The...

Continue Reading